Literature DB >> 2642585

Clostridium septicum infection and associated malignancy. Report of 2 cases and review of the literature.

A A Kornbluth1, J B Danzig, L H Bernstein.   

Abstract

We report 2 patients with myonecrosis due to Clostridium septicum and associated colon carcinoma and have reviewed the English language literature for all reported cases of atraumatic C. septicum infection. A total of 162 cases of C. septicum infection have been reported. Eighty-one percent of these patients had an associated malignancy. Thirty-four percent of all patients had associated colon carcinoma, while 40% had a hematologic malignancy. Thirty-seven percent of reported patients had an occult malignancy at the time of their infection with C. septicum. In many patients, the portal of entry was found in the large intestine. In a particularly lethal form (79% mortality) of C. septicum infection, known as "distant myonecrosis," infection metastatic from the initial site of infection causes severe myonecrosis, gangrene, and often death within hours of clinical detection. Overall, survival of patients with C. septicum infection is only 35%. Review of all cases of C. septicum infection suggests several conclusions. 1) Patients with malignancy, particularly colonic or hematologic, and patients with cyclic neutropenia who develop signs and symptoms of sepsis, especially with associated findings of abdominal pain or pain in an extremity, should be treated for possible clostridial infection. 2) C. septicum infection does not appear to be a result of a single specific defect in either humoral or cell-mediated immunity. Rather, it may occur in patients who are granulocytopenic and therefore prone to an enterocolitis. 3) Patients in whom an infection with C. septicum is found must undergo a vigorous search for malignancy following acute therapy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1989        PMID: 2642585     DOI: 10.1097/00005792-198901000-00002

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  49 in total

1.  Septic arthritis and Clostridium septicum: a clue to colon cancer.

Authors:  Joe Dylewski; Leonard Luterman
Journal:  CMAJ       Date:  2010-09-21       Impact factor: 8.262

2.  Aeromonas hydrophila: myofascial necrosis and sepsis.

Authors:  R B Vukmir
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

3.  Severe skin and soft tissue infections and associated critical illness.

Authors:  Donald C Vinh; John M Embil
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

4.  Clostridium septicum myonecrosis presenting as a parapharyngeal abscess in a patient with aplastic anemia.

Authors:  V G Fowler; C D Hamilton; C A Ohl
Journal:  Infection       Date:  1998 Sep-Oct       Impact factor: 3.553

5.  A rare cause of crepitus.

Authors:  H M Paterson; N Mamode
Journal:  Postgrad Med J       Date:  1998-01       Impact factor: 2.401

6.  Mycotic aneurysm caused by Clostridium septicum in a patient with colorectal cancer.

Authors:  Winesh Ramphal; Niels J Raaijmakers; Marjolein van der Klift; Jan H Wijsman; Jan A J W Kluytmans; Eelco J Veen
Journal:  Infection       Date:  2018-05-29       Impact factor: 3.553

7.  Purification and characterization of the lethal toxin (alpha-toxin) of Clostridium septicum.

Authors:  J Ballard; A Bryant; D Stevens; R K Tweten
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

Review 8.  Recovery of uncommon bacteria from blood: association with neoplastic disease.

Authors:  J L Beebe; E W Koneman
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

9.  Clostridium septicum infection and hemolytic uremic syndrome.

Authors:  M Barnham; N Weightman
Journal:  Emerg Infect Dis       Date:  1998 Apr-Jun       Impact factor: 6.883

10.  Anaerobic bacteria as a cause of mycotic aneurysm of the aorta: microbiology and antimicrobial therapy.

Authors:  Itzhak Brook
Journal:  Curr Cardiol Rev       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.